PVR and neoplasm: Moreover, IL-22 may contribute to sorafenib resistance of HCC through activating STAT3/CD155 signaling axis to decrease the sensitivities of tumor cells to sorafenib-mediated direct cytotoxicity and NK cell-mediated lysis.